Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10021


Purpose:

RATIONALE: Biological therapy such as lenalidomide use different ways to stimulate the immune system and stop tumor cells from growing. It may also stop the growth of tumor cells by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.


Study summary:

OBJECTIVES: Primary - Determine the best response in patients with advanced or unresectable renal cell cancer treated with lenalidomide (CC-5013). - Determine the time to disease progression in patients treated with this drug. Secondary - Determine the safety of this drug in these patients. OUTLINE: This is an open-label study. Patients receive oral lenalidomide (CC-5013) once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed at 30 days and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.


Criteria:

DISEASE CHARACTERISTICS: - Histologically confirmed renal cell carcinoma (RCC) - Advanced or unresectable disease - At least 1 measurable lesion - No active brain metastases - Prior brain metastases allowed provided patient has been treated with radiotherapy or surgery AND remains asymptomatic for ≥ 6 months PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 70-100% Life expectancy - Not specified Hematopoietic - Absolute neutrophil count ≥ 1,500/mm^3 - Platelet count ≥ 100,000/mm^3 Hepatic - Bilirubin ≤ 1.5 mg/dL - AST and ALT ≤ 2 times upper limit of normal (ULN) (5 times ULN if liver metastases are present) - No hepatitis A, B, or C infection Renal - Creatinine ≤ 2.0 mg/dL Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative - No known hypersensitivity to thalidomide - No other serious medical condition, laboratory abnormality, or psychiatric illness that would preclude giving informed consent - No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, localized prostate cancer, or superficial bladder cancer PRIOR CONCURRENT THERAPY: Biologic therapy - No more than 1 prior systemic immunotherapy regimen for RCC - No prior lenalidomide (CC-5013) - No prior or concurrent thalidomide Chemotherapy - No more than 1 prior systemic chemotherapy regimen for RCC Endocrine therapy - No more than 1 prior systemic hormonal therapy regimen for RCC Radiotherapy - See Disease Characteristics - No concurrent radiotherapy Surgery - See Disease Characteristics - At least 4 weeks since prior surgery and recovered Other - No more than 1 other prior systemic therapy regimen for RCC - No other concurrent anticancer therapies - No other concurrent investigational agents


NCT ID:

NCT00096525


Primary Contact:

Principal Investigator
Gnanamba V. Kondagunta, MD
Memorial Sloan-Kettering Cancer Center


Backup Contact:

N/A


Location Contact:

New York, New York 10021
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.